Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings
Xconomy
AUGUST 2, 2019
We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look at those companies. —Acadia Pharmaceuticals faced a setback in July with the failure of a late-stage trial that was testing pimavanserin —which the company’s sells under the name Nuplazid as a treatment for Parkinson’s disease-related psychosis—in people with schizophrenia who haven’t respond
Let's personalize your content